Trial
NCT02021929
Sorafenib for Hepatopulmonary Syndrome
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pennsylvania
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Condition
Hepatopulmonary Syndrome
Intervention
Sorafenib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-25